2-Butyl-3-(p-tolyl)quinuclidine
From Wikipedia, the free encyclopedia
|
2-Butyl-3-(p-tolyl)quinuclidine
|
|
| Systematic (IUPAC) name | |
| (7R,8S)-7-Butyl-8-(4-methylphenyl)-1-azabicyclo[2.2.2]octane | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C18H27N |
| Mol. mass | 257.414 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Legal |
| Routes | ? |
2-Butyl-3-(p-tolyl)quinuclidine (BTQ) is a stimulant drug which acts as a dopamine reuptake inhibitor.[1] It is one of a number of substituted quinuclidine derivatives developed as potential medications for the treatment of cocaine abuse,[2][3] and produces similar effects to cocaine in animal studies, although milder and longer lasting.
[edit] References
- ^ Sakamuri S, Enyedy IJ, Kozokowski AP, Wang S. Synthesis of 2-alkyl-3-aryl-substituted quinuclidines as novel dopamine transporter inhibitors. Tetrahedron Letters. 2000; 41:9949-9952.
- ^ Sakamuri S, Enyedy IJ, Zaman WA, Tella SR, Kozikowski AP, Flippen-Anderson JL, Farkas T, Johnson KM, Wang S. 2,3-Disubstituted quinuclidines as a novel class of dopamine transporter inhibitors. Bioorganic and Medicinal Chemistry. 2003 Mar 20;11(6):1123-36. PMID 12614900
- ^ Enyedy IJ, Sakamuri S, Zaman WA, Johnson KM, Wang S. Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors. Bioorganic and Medicinal Chemistry Letters. 2003 Feb 10;13(3):513-7. PMID 12565962

